Association between MTHFR (C677T) gene polymorphism with breast cancer in Northern Iran

WCRJ 2017; 4 (2): e876
DOI: 10.32113/wcrj_20176_876

  Topic: Breast cancer, Cancer diagnosis and molecular pathology     Category:

Abstract

Objective: Breast cancer is considered as the most common malignancies in women worldwide. Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) may affect the breast cancer risk by involving in folate metabolism and DNA methylation. This study was designed to examine the possible association of MTHFR gene polymorphism (SNP) in breast cancer susceptibility among the North Iranian women population.
Patients and Methods: We genotyped 677 C > T locus in 114 individuals that were classified into cases (N=54) and controls (N=60). Genotyping for MTHFR C677T was performed by polymerase chain reaction- restriction fragment length polymorphism (PCR- RFLP) using genomic DNA extracted from the peripheral blood of participant.
Results: The distribution of MTHFR (C677T) genotype frequencies, CC, CT, and TT among patients was 70.4%, 24.1%, and 5.6%, respectively. In the healthy control group, the CC, CT, and TT frequencies were 63.3%, 30%, and 6.7%, respectively. X2 analysis revealed that there was no significant association between breast cancer risk and MTHFR genotypes and alleles. Furthermore, no significant association was observed between C677T genotypes, estrogen, Her2 receptor, tumor stage, and grade.
Conclusions: The findings do not suggest that genetic variation in the MTHFR C677T polymorphism is involved in the breast cancer risk in a population of North Iranian patients.

To cite this article

Association between MTHFR (C677T) gene polymorphism with breast cancer in Northern Iran

WCRJ 2017; 4 (2): e876
DOI: 10.32113/wcrj_20176_876

Publication History

Submission date: 20 May 2017

Revised on: 30 May 2017

Accepted on: 12 Jun 2017

Published online: 27 Jun 2017